Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents

      

This page is updated frequently with new Vaccine-related patent applications.




Date/App# patent app List of recent Vaccine-related patents
08/18/16
20160237127 
 Recombinant peptide vaccines against ticks, and nucleotide sequences coding for the recombinant peptides patent thumbnailRecombinant peptide vaccines against ticks, and nucleotide sequences coding for the recombinant peptides
The present invention relates to the field of biotechnology and genetic engineering, and particularly to the expression of recombinant peptides. The inoculation thereof in cattle results in the production of an immune response capable of adversely affecting rhipicephalus microplus ticks, which feed on the inoculated cattle, decreasing the number and reproductive capacity of this tick species.
Patsos Endustria E Comercio De Produtos BiotecnolÓgicos Ltda


08/18/16
20160235840 
 Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same patent thumbnailCompositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
Nucleic acid molecules and compositions comprising: a nucleic acid sequence that encodes il-12 p35 subunit or a functional fragment thereof and/or a nucleic acid sequence that encodes il12 p40 subunit or a functional fragment thereof, are disclosed. The nucleic acid molecules and compositions further comprising a nucleic acid sequence that encodes an immunogen are also disclosed.
The Trustees Of The University Of Pennsylvania


08/18/16
20160235838 
 Vaccines with interleukin-33 as an adjuvant patent thumbnailVaccines with interleukin-33 as an adjuvant
Disclosed herein is a vaccine comprising an antigen and il-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof.
Inovio Pharmaceuticals, Inc.


08/18/16
20160235837 
 Therapies, vaccines, and predictive methods for middle east respiratory syndrome virus (mers cov) patent thumbnailTherapies, vaccines, and predictive methods for middle east respiratory syndrome virus (mers cov)
The present invention provides an isolated or synthesized protein fragment or peptide comprising at least one peptide sequence that is at least 50% homologous with at least one replikin peptide sequence identified in a mers cov. The at least one peptide sequence may be at least 80% homologous with at least one replikin peptide sequence identified in a mers cov.

08/18/16
20160235835 
 Influenza vaccines with reduced amounts of squalene patent thumbnailInfluenza vaccines with reduced amounts of squalene
Influenza vaccines include hemagglutinin from at least one influenza a virus strain and at least one influenza b virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene.
Seqirus Uk Limited


08/18/16
20160235834 
 Live attenuated vaccines patent thumbnailLive attenuated vaccines
The present invention refers to a method for the production of live attenuated bacterial strains, suitable as vaccine candidates, comprising the steps of: a. Providing a bacterial strain capable of expressing glutamate racemase and possibly d-amino acid transaminase and comprising a peptidoglycan cell wail, and b.
FundaciÓn Profesor Novoa Santos


08/18/16
20160235832 
 Compositions and the use of fibrinogen binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery patent thumbnailCompositions and the use of fibrinogen binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, c3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified n-terminus region, at least a portion of a modified c-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.. .
University Medical Center Utrecht, The Netherlands


08/18/16
20160235831 
 Process for stabilizing an adjuvant containing vaccine composition patent thumbnailProcess for stabilizing an adjuvant containing vaccine composition
The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form.. .
Sanofi Pasteur Sa


08/11/16
20160230139 
 Self-contained device and system to produce ex-vivo autologous whole cell tumor vaccines patent thumbnailSelf-contained device and system to produce ex-vivo autologous whole cell tumor vaccines
The invention disclosed herein aims to standardize and simplify the process of preparing ex-vivo autologous whole tumor cell vaccines. The present invention is a robust, stand-alone device and system for preparing autologous tumor cell vaccines in a completely self-contained sterile environment, and in a shortened time.

08/11/16
20160229897 
 Hepatitis b virus vaccines patent thumbnailHepatitis b virus vaccines
This document provides methods and materials for producing immune responses against hepatitis b viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis b viruses within mammals (e.g., humans) are provided..
Altravax, Inc.


08/11/16
20160228536 

Recombinant respiratory syncytial virus (rsv) and vaccines


Described herein is a recombinant respiratory syncytial virus (rsv) having an attenuated phenotype. In one embodiment, recombinant rsv includes an m2-2 protein with a mutation that renders the m2-2 protein inactive or prevents expression of the m2-2 protein.
Medimmune, Llc


08/11/16
20160228535 

Influenza virus mutants and uses therefor


Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines.
Flugen, Inc.


08/11/16
20160228534 

Influenza virus mutants and uses therefor


Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines.
Flugen, Inc.


08/11/16
20160228532 

Method of obtaining thermostable dried vaccine formulations


This present invention relates to compositions and methods for stabilizing a dried vaccine formulations. In particular, the invention provides a method for producing a vaccine composition comprising the steps of providing an aqueous composition comprising a buffer, the vaccine components and between 17.5% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, and applying microwave radiation under a pressure lower than atmospheric pressure in order to sublimate the composition and obtain a dried vaccine formulation.
Merck Sharp & Dohme Corp.


08/11/16
20160228529 

Meningococcal vaccine formulations


A dual formulation for vaccines against neisseria meningitidis serogroup b (‘men-b’) comprises (i) an oil-in-water emulsion adjuvant and (ii) a men-b immunogenic component in lyophilised form. The lyophilised men-b antigens can be reconstituted into liquid adjuvanted form at the time of use ready for administration to a patient.
Glaxosmithkline Biologicals Sa


08/11/16
20160228528 

A single or multistage mycobacterium avium subsp. paratuberculosis subunit vaccine


The present invention provides one or more immunogenic polypeptides for use in a preventive or therapeutic vaccine against latent or active infection in a human or animal caused by a mycobacterium species, e.g. Mycobacterium avium subsp.
Janssen Sciences Ireland Uc


08/11/16
20160228525 

Malaria vaccine


Embodiments are directed to malaria vaccines comprising a bacteriophage vlp displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.. .
Leidos, Inc.


08/11/16
20160228445 

6-amino-purin-8-one compounds


Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..

08/11/16
20160228369 

Dry formulations of vaccines that are room temperature stable


The present invention discloses dry formulations of room temperature stable vaccines that comprise a live attenuated virus, a sugar stabilizer, and an amino acid stabilizer. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines..
Intervet Inc.


08/11/16
20160228368 

Fixation of vaccine formulations on devices for epidermal immunisation by oily adjuvants


The present patent application relates to a pharmaceutical product and a device for the storage, handling, transport and administration of active ingredients, pharmaceutical formulations and vaccines. In addition, the present invention relates to a device and pharmaceutical product suitable for intra-dermal, intra-mucosal or epidermal administration like for example intra-dermal or epidermal immunisation.
Lts Lohmann Therapie-systeme Ag


08/04/16
20160222343 

Compositions containing amino acids, phosphate and manganese and their uses


The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.


08/04/16
20160222070 

Compounds and methods for diagnosis and immunotherapy of tuberculosis


Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more mycobacterium proteins and dna molecules encoding such polypeptides.
Corixa Corpoation


08/04/16
20160220670 

Boosting the efficacy of dna-based vaccines with non-thermal dbd plasma


The efficacy of a dna-based vaccine in terms of eliciting a desired immune response is enhanced by directing a non-thermal plasma generated by a non-thermal plasma generator at the site on the patient's skin where the vaccine was previously introduced.. .
Ep Technologies Llc


08/04/16
20160220666 

Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc


08/04/16
20160220661 

Broad spectrum influenza a neutralizing vaccines and d-peptidic compounds, and methods for making and using the same


Gb1 peptidic compounds that specifically bind to a hemagglutinin target protein, and libraries that include the same, as well as methods of making and using the same, are provided. Also provided are methods and compositions for making and using the compounds.
The Governing Council Of The University Of Toronto


08/04/16
20160220659 

Fmdv recombinant vaccines and uses thereof


The present invention encompasses fmdv vaccines or compositions. The vaccine or composition may be a vaccine or composition containing fmdv antigens.
Merial, Inc.


08/04/16
20160220653 

Lyme disease vaccines


The present invention relates to lyme disease vaccines, in particular to vaccines including one or more isolated polypeptides of borrelia burgdorferi ss, borrelia afzelii or borrelia garinii.. .
Centre National De La Recherche Scientifique - Cnrs


08/04/16
20160220483 

Thermally stable vaccine formulations and microneedles


Formulations and methods are provided for stabilizing antigens in dry solid vaccines. One aspect relates to dry solid formulations of influenza vaccines including one or more excipients identified as imparting stability to influenza antigens.
Georgia Tech Research Corporation


07/28/16
20160216276 

Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines


Disclosed herein are diagnostic assays for identifying individuals that are protected against plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects.
The United States Of America,as Represented By The Secretary, Department Of Health And Human Service


07/28/16
20160216263 

Porcine torque teno virus vaccines and diagnosis


The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine torque teno virus (pttv) genotypes or subtypes pttv1a-va, pttv1b-va, pttv2b-va, and pttv2c-va. The present invention also provides infectious dna clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same.
Virginia Tech Intellectual Properties, Inc.


07/28/16
20160215056 

Human immune therapies using a cd27 agonist alone or in combination with other immune modulators


Methods of inducing t cell proliferation and expansion in vivo for treating conditions wherein antigen-specific t cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one cd27 agonist, preferably an agonistic cd27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-cd40, ox-40, 4-1bb, or ctla-4 antibody or an agent that depletes regulatory cells, or a cytokine.
University Of Southampton


07/28/16
20160215040 

Human antibodies to ebola virus glycoprotein


The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing ebola virus activity, thus providing a means of treating or preventing ebola virus infection in humans.
Regeneron Pharmaceuticals, Inc.


07/28/16
20160215032 

Influenza nucleoprotein vaccines


The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from influenza strain a, b or c, and a variant of a c4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease..
Imaxio


07/28/16
20160215023 

Simple vaccines from dna launched suicidal flaviviruses


Immunogenic compositions relating to dna launched suicidal flaviviruses and methods of administering the same are described herein.. .
Chontech Pharma Ab


07/28/16
20160213769 

Vaccine formulation


The present invention relates to immunological compositions and vaccines that target diseases caused by infection with streptococcus pyogenes. In particular, the compositions of the present invention find use in therapeutic and/or prophylactic methods for the treatment or prevention of morbidity associated with infection with streptococcus pyogenes.
Vaxform Llc


07/28/16
20160213766 

Ospa fusion protein for vaccination against lyme disease


Provided herein are monocot seed compositions and methods of making a monocot seed product expressing high levels of recombinant osp fusion protein. In some embodiments, a rice seed composition is used in the manufacture of a lyme disease vaccine formulation.
Ventria Bioscience, Inc.


07/28/16
20160213764 

Composite tissue cancer vaccine


Disclosed are composite cancer vaccines, in one embodiment generated through 3-dimensional bioprinting or through inoculation of roller cultures. The utilization of decellularized biological matrices such as placental tissue or subintestinal submucosal tissue is disclosed as a substrate for 3-dimensional tissue culture.
Batu Biologics, Inc.


07/28/16
20160213763 

Novel glycan conjugates and methods of use thereof


The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the ssea3/ssea4/globoh associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis.
Academia Sinica


07/28/16
20160213761 

Carbon nanotube compositions and methods of use thereof


Carbon nanotube (cnt)-based compositions for activating cellular immune responses are provided. The cnts function as high surface area scaffolds for the attachment of t cell ligands and/or antigens.
Yale University


07/21/16
20160208223 

High titer recombinant influenza viruses for vaccines


The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes at least five internal genes from an influenza virus isolate that replicates to high titers in embryonated chicken eggs or mdck cells.. .
Wisconsin Alumni Research Foundation (warf)


07/21/16
20160207964 

Designing a soluble full-length hiv-1 gp41 trimer


Described herein is a soluble hiv-1 retrovirus transmembrane glycoprotein gp41 trimer (soc-gp41m-fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (soc) protein of bacteriophage t4 and the foldon domain of the bacteriophage t4 fibritin (fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of hiv-1 vaccines, diagnostics and therapeutics.
The Catholic University Of America


07/21/16
20160206728 

Dried influenza vaccine preparation and producing the same


The present invention provides a dried influenza vaccine preparation in which the activity of an influenza vaccine antigen can be stably maintained even when stored without strictly maintaining a low temperature, and which can be stably supplied. The present invention also provides a method of producing the dried influenza vaccine preparation.
Nitto Denko Corporation


07/21/16
20160206724 

Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (lav)


Disclosed are compositions and methods related to recombinant arenaviruses and their use in vaccines for the treatment or prevention of an arenavirus infection.. .
University Of Rochester


07/21/16
20160206721 

Bacterial vaccine and methods for manufacture thereof


Disclosed are stable conjugate vaccine formulations for protection against salmonella typhi, and methods of conjugation between vi-polysaccharide of s. Typhi to tetanus toxoid as the carrier protein, responsible for producing improved t-dependent immune response against typhoid fever caused by salmonella typhi.
Bharat Botech International Limited


07/21/16
20160206720 

Potomac horse fever isolates


The present invention discloses novel isolates of neorickettsia risticii, compositions comprising such isolates, vaccines and methods for using such vaccines against potomac horse fever.. .
Intervet Inc.


07/21/16
20160206716 

Compositions comprising angiogenic factors and methods of use thereof


The present invention provides recombinant listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a pest-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.. .
The Trustees Of The University Of Pennsylvania


07/21/16
20160206715 

Specific multivalent virus-like particle vaccines and uses thereof


The invention provides a vlp free of a viral genome comprising two or more display polypeptides, nucleic acid molecules, polymers of the nucleic acid, lipopolysaccharides, lipopeptides, peptidoglycans and/or small molecules.. .
The Board Of Trustees Of The Leland Standford Junior University


07/14/16
20160200801 

Monoclonal antibodies capable of reacting with a plurality of influenza virus a subtypes


Monoclonal antibodies directed against the influenza a virus are described, which have the advantageous and unpredicted property of being able to bind a plurality of subtypes of the influenza a virus. One preferred embodiment is the antibody designated as fab28, which displays a neutralizing activity against a plurality of subtypes of the influenza a virus.
Pomona Ricerca S.r.l.


07/14/16
20160200774 

Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines


This invention relates, e.g., to a virus-like particle (vlp) composition assembled from a chimeric polypeptide comprising a papilloma virus (e.g., human papillomavirus, or hpv) l1 major capsid protein, into which is inserted a surface-displayed peptide comprising a neutralizing epitope of a papillomavirus l2 protein. vaccine compositions comprising the vlp are described, as well as methods for inducing an immune response (e.g., vaccinating) a subject against papilloma virus, using the vlp, and kits comprising the vlp, for carrying out a method of the invention..
The Johns Hopkins University


07/14/16
20160200764 

Peptide vaccines for cancers expressing tumor-associated antigens


The present invention provides peptides having an amino acid sequence as set forth in seq id no: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic t cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the cdh3, epha4, ect2, hig2, inhbb, kif20a, kntc2, ttk and/or urlc10, e.g.
Oncotherapy Science, Inc.


07/14/16
20160200758 

1,2,3-triazole-tethered carbohydrate-di and tri lipidated cysteine conjugates useful as vaccine adjuvants and process for preparation thereof


The present invention also provides process for preparation of carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles. The carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles as vaccine adjuvants are useful in formulations for therapeutic and prophylactic vaccines against bacterial, viral, protozoan infections and cancer..

07/14/16
20160199522 

Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders


Methods for detecting α-synuclein oligomers in vivo comprise administering an antibody to an individual suspected of carrying soluble α-synuclein, wherein the antibody is produced from a stabilized soluble α-synuclein oligomer and is capable of binding the stabilized soluble α-synuclein oligomer, wherein the stabilized soluble α-synuclein oligomer has a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein, and wherein the antibody is labelled with a detectable marker; and detecting the presence of any complex formed between the antibody and soluble α-synuclein by detection of the marker.. .
Bioarctic Neuroscience Ab


07/14/16
20160199504 

Development of novel macromolecule transduction domain with improved cell permeability and using same


The present invention relates to an improved macromolecule transduction domain (mtd), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved mtd according to the present invention, compared to an existing mtd, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like.
Procell Therapeutics Inc.


07/14/16
20160199481 

Compositions and methods for directed immunogen evolution and uses thereof


The present disclosure relates to compositions and methods for using a modified virus that infects a cell only if the virus presents a candidate antigen that binds with high affinity to a target antibody, thereby allowing for generation and identification of immunogens useful, for example, as vaccines.. .
Fred Hutchinson Cancer Research Center


07/14/16
20160199478 

Enveloped virus vaccine and production


The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified ross river virus (rrv) antigens, and vaccines comprising purified, inactivated ross river virus (rrv) antigen..
Baxter Healthcare Sa


07/14/16
20160199477 

Attenuated mannheimia haemolytica vaccines and methods of making and use


The present invention provides attenuated m. Haemolitica strains that elicit an immune response in animal against m.
Merial Inc.


07/14/16
20160199473 

Mesothelin vaccines and model systems


Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic t cell response.
The Johns Hopkins University


07/14/16
20160199440 

Designed peptides for tight junction barrier modulation


According to aspects illustrated herein, there is provided an agent that transiently disrupts claudin-1 within tight junctions. The agent includes a peptide having at least 40% polar, uncharged amino acid residues and a self-assembled β-sheet secondary structure.
University Of Rochester


07/07/16
20160194663 

Replication-defective arenavirus vectors


The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (gp), nucleoprotein (np), matrix protein z and rna-dependent rna polymerase l are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral rna-dependent rna polymerase, cellular rna polymerase i, rna polymerase ii or rna polymerase iii.
UniversitÄt ZÜrich


07/07/16
20160194662 

Recombinant virus-like particles encoded by multi-gene vector


The invention describes novel virus-like particles for use as vaccines, diagnostic tools and r&d tools based on recombinant dna and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts.
Pfizer Inc.


07/07/16
20160194377 

Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof


The present invention discloses crystal structure of staphylococcus aureus clumping factor a (clfa) in complex with fibrinogen (fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of clfa targeted vaccines and therapeutic agents (including monoclonal antibodies).
The Texas A&m University System


07/07/16
20160193350 

Phosphorylcholine conjugates and uses thereof


The present invention provides phosphorylcholine (pc)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the pc-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


07/07/16
20160193330 

Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc


07/07/16
20160193326 

Vaccine compositions for drug addiction


The present invention relates generally to vaccines for drug addiction. In particular, the present disclosure provides adjuvants for significantly improving immune responses generated against addictive drug haptens..
Immune Design Corp.


07/07/16
20160193321 

Making influenza virus vaccines without using eggs


Currently, the steps performed prior to release of influenza strains to vaccine manufacturers involve passaging influenza virus through eggs. The invention aims to provide procedures useful in manufacturing influenza vaccines, in which the use of eggs is reduced, and preferably is avoided altogether.
Novartis Ag


07/07/16
20160193316 

Inducing cellular immune responses to plasmodium falciparum using peptide and nucleic acid compositions


This invention uses our knowledge of the mechanisms by which antigen is recognized by t cells to identify and prepare plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria.
Epimmune Inc.


07/07/16
20160193315 

Peptides shared among lethal cancers and therapeutic compositions comprising said peptides


The present invention provides cancer peptides related to rapid replication and shared among different histological cancer types. The peptides are provided in compositions for interfering with replication in cancer, in preventive and therapeutic vaccines, and in diagnostic applications.

07/07/16
20160193310 

Rm2 antigens and use thereof


Described herein are synthetic glycan conjugates, immmunogenic compositions thereof, vaccines thereof, and kits thereof. The present invention further provides methods of using the synthetic glycan conjugates, immunogenic compositions, or vaccines thereof to treat and/or prevent and/or diagnose proliferative diseases such as cancer.
Academia Sinica


06/30/16
20160187351 

Method for the absolute quantification of naturally processed hla-restricted cancer peptides


The present invention relates to a method for the absolute quantification of naturally processed hla-restricted cancer peptides, i.e. The determination of the copy number of peptide(s) as presented per cell.

06/30/16
20160186260 

Cancer vaccination with antigen evolution


The invention provides methods for treating with cancer vaccines patients whose cancers undergo clonal evolution. The invention makes use of a series of cancer vaccines to stimulate a patient's immune system to mount both a humoral and cellular immune response against cancer cells as cancer-specific antigens on the cancer cells change by clonal evolution.

06/30/16
20160186158 

Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis


Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising leishmania antigens as well as polynucleotides encoding such polypeptides..

06/30/16
20160185865 

Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use


The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.

06/30/16
20160185831 

Nucleic acids for treatment of allergies


The present invention provides dna vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (lamp) and the targeting sequence of lamp.

06/30/16
20160185827 

Vaccines for preventing meningococcal infections


The present invention stems from the finding that the interaction between the β2 adrenoceptor (β2ap) and type iv pilus-associated proteins initiates a process leading to the opening of the blood-brain barrier. The invention therefore pertains to a vaccine for preventing the spreading of meningococci into the meningeal space, wherein said vaccine allows the production of antibodies inhibiting the interaction between the type iv pilus-associated proteins and the β2ap..

06/30/16
20160185826 

Virus-like particle vaccines


The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof.

06/30/16
20160184421 

Immunotherapeutic targets against staphylococcus aureus


The subject invention pertains to vaccine formulations and antibodies, and related methods, for the treatment and/or prevention of s. Aureus infection.

06/23/16
20160176985 

Humanized monoclonal antibodies and methods of use


The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.

06/23/16
20160176975 

Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies


The present invention provides a method for inducing a cancer specific immune response against muc1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide.

06/23/16
20160176953 

Human antibodies to influenza hemagglutinin


The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza hemagglutinin (ha) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing influenza virus activity, thus providing a means of treating or preventing influenza infection in humans.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.035

4744

3 - 0 - 101